Trial Profile
A retrospective study to determine predictive factors for disease-free survival and pathological complete response after neoadjuvant chemotherapy with trastuzumab in patients with HER2-positive primary breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms JBCRG-C03
- 23 Apr 2014 New trial record